1. Tomografía en la evaluación del cáncer pulmonar: comparación de los criterios RECIST 1.1 vs. mediciones convencionales e impacto en la respuesta al tratamiento.
- Author
-
Cuituny-Romero, A. K., Onofre-Castillo, J., Valero-Castillo, R., Santana-Vela, I. A., and Torres-Gómez, E.
- Abstract
INTRODUCTION: the incidence lung cancer has risen 25% in recent years with 10% survival at 5 years. Response to treatment needs to be evaluated using the Response Evaluation Criteria in Solid Tumors (RECIST) and conventional measuring methods. PURPOSE: stage response to treatment with the RECIST, comparing such measurements with the conventional radiological method. MATERIAL AND METHOD: we studied 51 patients in the period January 2012 to September 2015 with histological diagnosis of lung carcinoma. RESULTS: statistically significant difference in the RECIST group was observed in the baseline and follow-up studies compared with conventional methods. There was no significant difference between the three measuring methods in baseline and follow-up studies in evaluation of target lesions; we propose that the three measuring methods can be used in evaluating target lesions. Because the T test showed statistically significant difference between baseline and follow-up evaluations of the one-dimensional method, we recommend using it in global evaluation of response to treatment. CONCLUSION: the RECIST are superior to conventional methods because they include non-target lesions, new lesions to assign global response, where the latter was changed to include the aforementioned lesions, altering the classification of response to treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2017